How would you manage biopsy-proven DLBCL in a patient who was treated with 6 cycles of R-CHOP 15 years ago for DLBCL?   

Would you consider this de novo DLBCL (unable to assess for clonality)? How would you handle prior anthracycline exposure? 



Answer from: Medical Oncologist at Academic Institution